Combined Compression and Cooling Therapy for Taxane Chemotherapy-induced Peripheral Neuropathy in Lung Cancer

Area of Science:

• Oncology
• Neuroscience
• Pharmacology

Background:

• Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, disabling adverse effect of taxane chemotherapy.
• Lung cancer patients receiving taxanes are at high risk for developing CIPN.
• Effective prevention strategies for CIPN are crucial to maintain treatment adherence and quality of life.

Purpose of the Study:

• To evaluate the efficacy of a combined compression and cooling therapy in preventing CIPN.
• To assess the safety and feasibility of this non-pharmacologic intervention.
• To determine the impact of this therapy on taxane-treated lung cancer patients.

Main Methods:

• Retrospective analysis of 53 advanced lung cancer patients undergoing taxane-based chemotherapy.
• Implementation of combined compression (surgical gloves, elastic stockings) and cooling (ice pillows) during infusions.
• Monitoring of CIPN incidence, severity, and treatment modifications.

Main Results:

• A low overall incidence of CIPN (20.8%) was observed.
• No patients experienced grade ≥3 neuropathy; paclitaxel and nab-paclitaxel regimens showed lower CIPN rates than docetaxel.
• The therapy was well-tolerated, with mild, reversible adverse events and no chemotherapy dose reductions.

Conclusions:

• Combined compression and cooling therapy is a safe and feasible non-pharmacologic option for CIPN prevention in lung cancer patients.
• This approach may help mitigate a common side effect of taxane chemotherapy.
• Further prospective studies are recommended to validate these findings.